A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Singh Dave; Boguş Maxim; Moskalenko Valentyn; Noi Autori

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

164

SM ISO690:2012

SINGH, Dave, BOGUŞ, Maxim, MOSKALENKO, Valentyn, NOI, Autori. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 . In: European Respiratory Journal, 2021, vol. 58, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.00673-2021

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

European Respiratory Journal

Volumul 58 / 2021 / ISSN 0903-1936 /ISSNe 1399-3003

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

DOI:https://doi.org/10.1183/13993003.00673-2021

Pag. 0-0

Singh Dave¹²³, Boguş Maxim⁴, Moskalenko Valentyn⁵, Noi Autori

¹ University of Manchester,
² Kyiv City Oleksandrivska Clinical Hospital,
³ Brovary multidisciplinary clinical hospital,
⁴ Timofei Moșneaga Republican Clinical Hospital,
⁵ Kyiv City Clinical Hospital #12

Disponibil în IBN: 19 iulie 2023

Cuvinte-cheie
MeSH Administration, inhalation, COVID-19, Humans, Janus Kinase Inhibitors, Janus Kinases, SARS-CoV-2 EMTREE drug terms advanced glycation end product receptor, C reactive protein, dexamethasone, heparin, nezulcitinib, placebo, remdesivir, Janus kinase, Janus kinase inhibitor EMTREE medical terms adult, arterial oxygen saturation, clinical article, controlled study, coronavirus disease 2019, double blind procedure, drug dose escalation, drug dose increase, drug safety, drug tolerability, drug withdrawal, female, fraction of inspired oxygen, human, hypertransaminasemia, invasive ventilation, letter, loading drug dose, Male, maximum plasma concentration, Moldova, mortality rate, multicenter study, phase 2 clinical trial, Pulse oximetry, Randomized controlled trial, Respiratory failure, respiratory tract parameters, SaO2 FIo2 ratio, side effect, Ukraine, United Kingdom, clinical trial, inhalational drug administration